<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36863">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01964521</url>
  </required_header>
  <id_info>
    <org_study_id>MxT Ag 05</org_study_id>
    <nct_id>NCT01964521</nct_id>
  </id_info>
  <brief_title>TITLE: An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended</brief_title>
  <acronym>MxT Ag 05</acronym>
  <official_title>An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molnlycke Health Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molnlycke Health Care AB</source>
  <oversight_info>
    <authority>United Kingdom: National Research Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open, non-comparative, multi-centre post marketing clinical follow-up, PMCF,
      investigation to evaluate performance and safety on diabetic foot ulcer, dfu, when using
      mepilex transfer Ag as intended.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>changes in signs and symptoms of local infection</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>levels of pain in connetion to dressing changes.</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Mepilex Transfer Ag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mepilex Transfer Ag</intervention_name>
    <arm_group_label>Mepilex Transfer Ag</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Both gender&gt;=18 years old

          2. Subjects with type 1 or 2 diabetes mellitus

          3. Two of the signs of infection must be present and recorded (redness, heat, oedema,
             pain, increased exudates amount, deteriorating wound, fever, odour)

          4. Ulcer localization; below the ankle

          5. Signed Informed Consent

        Exclusion Criteria:

          1. Dry wound

          2. Known allergy/hypersensitivity to the dressing

          3. Treated with other Silver dressing on the ulcer target within 1 week prior to this
             investigation

          4. Subjects who will have problems following the clinical investigation plan

          5. Subjects enrolled in the investigation already

          6. Subjects included in other ongoing clinical investigation at present or during the
             past 30 days. Subjects participating in a clinical sample investigation  might be
             enrolled in the investigation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ketan Dhatariya, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norfolk &amp; Norwich University Hospitals NHS foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ketan Dhatarlya, doctor</last_name>
    <email>ketan.dhatariya@nnuh.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Norfolk &amp; Norwich University Hospitals NHS foundation</name>
      <address>
        <city>Norwich</city>
        <state>Colney Lane</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ketan Dhatariya, doctor</last_name>
      <email>ketan.dhatariya@nnuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ketan Dhatariya, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Rotherham NHS Foundation Trust</name>
      <address>
        <city>Rotherham</city>
        <zip>S60 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Franke, Doctor</last_name>
      <phone>01709/304157</phone>
    </contact>
    <investigator>
      <last_name>Bernd Franke, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>September 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
